Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com - Gamida Cell reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Gamida Cell announced earnings per share of $-0.290 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.310 on revenue of $0.
Gamida Cell 's are down 45% and is trading at $1.960 , still down 58.47% from its 52 week high of $4.72 set on Wednesday, March 30, 2022.
Gamida Cell shares lost 6.67% to trade at $1.960 in intra-day trade the report.
Gamida Cell follows other major Healthcare sector earnings this month
Gamida Cell's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar